Jade Biosciences (JBIO) financial statements
Net income was -$127M.
Free cash flow was -$95M.
The diluted share count rose 12846% over the period (dilution).
Income statement
Fiscal years, from Jade Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Research and development | $8M | $15M | $39M | $64M | $53M | $93M |
| Selling, general and admin | $949,000 | $8M | $15M | $17M | $21M | $20M |
| Operating income | -$9M | -$23M | -$53M | -$81M | -$75M | -$114M |
| Interest expense | $75,000 | — | — | — | — | — |
| Pre-tax income | -$10M | -$23M | -$51M | -$75M | -$70M | -$127M |
| Income tax | — | $3,000 | $25,000 | $56,000 | $55,000 | $58,000 |
| Net income | -$10M | -$23M | -$52M | -$76M | -$70M | -$127M |
| EPS (diluted) | -$40.31 | -$1.87 | -$2.10 | -$2.87 | -$2.44 | -$3.19 |
| Diluted shares | 0M | 12M | 24M | 26M | 29M | 31M |
Balance sheet
Fiscal years, from Jade Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $5M | $167M | $129M | $122M | $79M | $336M |
| Total current assets | $5M | $174M | $131M | $124M | $70M | $349M |
| Property, plant and equipment | $39,000 | $186,000 | $242,000 | $288,000 | $0 | $170,000 |
| Total assets | $5M | $175M | $135M | $127M | $73M | $350M |
| Total current liabilities | $2M | $3M | $8M | $18M | $12M | $17M |
| Total liabilities | $2M | $3M | $9M | $18M | $120M | $17M |
| Shareholders' equity | -$13M | $172M | $127M | $109M | -$47M | $333M |
| Net debt | -$5M | -$54M | -$22M | -$23M | -$69M | -$88M |
Cash flow
Fiscal years, from Jade Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8M | -$27M | -$39M | -$57M | -$71M | -$95M |
| Capital spending | — | $181,000 | $195,000 | $142,000 | — | $196,000 |
| Free cash flow | — | -$28M | -$39M | -$57M | — | -$95M |
| Stock-based compensation | $58,000 | $2M | $5M | $12M | $11M | $20M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for JBIO.
Open JBIO in InvestinglyQuestions
How much free cash flow does Jade Biosciences generate?
-$95M in fiscal 2025 (operating cash flow minus capital spending).
From Jade Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.